Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polypeptide N-acetylgalactosaminyltransferase 13 (GALNT13)
- Target
- GALNT13
- Molecular classification
- Enzyme, Glycosyltransferase
01
Overview
Polypeptide N-acetylgalactosaminyltransferase 13 (GALNT13) is an enzyme belonging to the glycosyltransferase family that initiates O-linked glycosylation of mucins and other glycoproteins by transferring N-acetylgalactosamine (GalNAc) from UDP-GalNAc to serine or threonine residues on substrate proteins[1][2][7]. This catalysis generates the Tn antigen, which is important in cell biology and immunology and serves as a precursor for various mucin-type O-glycan structures[1][6][7]. GALNT13 is expressed particularly in the brain and central nervous system, where it may contribute to neurogenesis via glycosylation of PDPN[1][5]. Disease associations include cancers such as lung cancer, and classic Ehlers-Danlos syndrome[1][8].
- Other names
- GALNT13GalNAc-T13KIAA1918pp-GaNTase 13Protein-UDP acetylgalactosaminyltransferase 13UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 13UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13Polypeptide GalNAc transferase 13
02
Biological functions
O-linked glycosylation of proteins, especially mucinsGeneration of Tn antigen (GalNAc-O-Ser/Thr structure)Promotion of neurogenesis through PDPN glycosylation and stabilization (central nervous system)
03
Disease associations
Cancer (notably lung cancer, where high mRNA expression is linked to poor prognosis)Ehlers-Danlos Syndrome, Classic Type, 1Other neurological roles (brain expression, neurogenesis)
04
Safety considerations
No explicit safety concerns, but targeting glycosylation can have widespread cellular effects.
05
Biomarkers
Tn antigen (immunogenic modification generated by GALNT13 activity)GALNT13 mRNA expression (associated with poor prognosis in lung cancer)
Beyond the preview
Go deeper on Polypeptide N-acetylgalactosaminyltransferase 13 (GALNT13).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polypeptide N-acetylgalactosaminyltransferase 13 (GALNT13).